Curaleaf (OTCMKTS:CURLF – Get Free Report) and TBG Diagnostics (OTCMKTS:TDLAF – Get Free Report) are both consumer discretionary companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.
Valuation & Earnings
This table compares Curaleaf and TBG Diagnostics’ top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Curaleaf $1.35 billion 2.65 -$281.20 million ($0.39) -14.10 TBG Diagnostics $2.33 million 1.02 $530,000.00 N/A N/A
TBG Diagnostics has lower revenue, but higher earnings than Curaleaf.
Risk and Volatility Curaleaf has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500. Comparatively, TBG Diagnostics has a beta of -12.38, suggesting that its stock price is 1,338% less volatile than the S&P 500. Analyst Ratings
This is a breakdown of current ratings and recommmendations for Curaleaf and TBG Diagnostics, as provided by MarketBeat.com.
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Curaleaf 1 1 3
